 PLANEGGMUNICH, GERMANY ACCESSWIRE May 19, 2021 MorphoSys AG FSE:MORNASDAQ:MOR today announced that new data from the tafasitamab MonjuviR development program will be presented at the upcoming 2021 American Society of Clinical Oncology ASCO Annual Meeting from June 4-8, 2021. Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, which was approved as MonjuviR tafasitamab-cxix in July 2020 by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant ASCT. 